Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label induction trial of Ozanimod in moderately to severely active Crohn's disease
2015-002025-19Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ozanimod in Crohn's disease (2 arms), sponsored by Celgene Corporation. Primary endpoint: Change in SES-CD from baseline at Week 12. Started Oct 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-002025-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002025-19.